Animal & Veterinary Health

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Portable, low-dose 3D X-ray technology sits at the core of what Adaptix brings to medical, veterinary, and industrial imaging. Rather than tethering clinicians and engineers to fixed installations, the company's platform is built around a "3D first" philosophy, making volumetric imaging accessible at the point of care and in field environments where conventional CT infrastructure is impractical. In medical imaging, Adaptix focuses on reshaping diagnostic pathways. Its Ortho350 system targets orthopaedic applications, offering rapid access to 3D imaging in clinical practice without the footprint or cost burden of traditional CT. The company positions itself as a driver of point-of-care diagnostics , enabling professionals to capture the diagnostic quality they need outside of radiology departments. The veterinary offering extends the same approach into practice-based settings. The VetSA3D system addresses both standard companion animal imaging and exotics imaging, providing 3D diagnostic capability at a fraction of conventional CT cost, which is a meaningful advantage in specialist veterinary practice. Adaptix also operates a significant industrial imaging division under its NDT3D product line. Applications include non-destructive testing of composite structures, additive-manufactured metals, large battery assemblies, and electronic components. The move from 2D to 3D inspection is presented as delivering richer analytical insight, faster workflows, and greater confidence in quality decisions, particularly relevant to advanced manufacturing sectors. The breadth of markets served, spanning medical, dental, veterinary, and industrial inspection, reflects a platform technology strategy rather than a single-sector focus. Adaptix distributes internationally through a partner network. Further information is available at adaptix.com.

With a robust network of advanced manufacturing sites across Europe and the United States, Aenova Group operates as one of the world's most trusted contract development and manufacturing organisations (CDMOs) serving the pharmaceutical and healthcare industries. The group provides end-to-end solutions that span the entire product lifecycle, from early-stage formulation and process development through to large-scale commercial manufacturing. End-to-End Manufacturing and Development Capabilities Aenova's service portfolio covers contract production, pharmaceutical packaging , drug product development, and third-party manufacturing across a broad range of dosage forms. The group applies state-of-the-art facilities and cutting-edge technologies to deliver tailored solutions for pharmaceutical, consumer health, and veterinary markets worldwide, including a dedicated animal health division. Global Reach Across Pharmaceutical, Consumer Health, and Veterinary Markets Formed through a series of strategic mergers and acquisitions, Aenova has grown into a globally recognised CDMO partner with manufacturing capacity concentrated across European sites and the United States. The group's international footprint allows clients to access scalable, compliant manufacturing services throughout multiple regulatory jurisdictions. Aenova also maintains dedicated functions covering corporate sustainability, compliance, and investor relations, reflecting the governance infrastructure of a major industry participant. Further information is available at aenova-group.com.

Peer-reviewed publishing dedicated to the global animal health sector defines the work of International Animal Health Journal , a specialist B2B media title covering the regulatory, operational and commercial dimensions of veterinary medicines, veterinary devices and animal food. The journal provides industry professionals, contract service providers and regulatory affairs teams with substantive editorial on outsourcing in animal health , positioning it as a reference title for practitioners navigating a sector that operates under comparable compliance frameworks to human pharmaceuticals yet carries distinct regulatory requirements across major markets including the EU, US and UK. The publication maintains a structured editorial archive spanning ten volumes, with multiple issues produced per year, reflecting a sustained output that covers topic areas such as veterinary drug development, animal nutrition, supply chain management and the evolving regulatory landscape for veterinary products. Content is accessible through current features, archived issues and an alphabetically organised company profile directory, giving readers both timely industry news and a supplier intelligence resource. Although listed under Clinical Research in some classification systems, the journal's primary function is B2B trade media rather than clinical research provision. Its readership includes contract manufacturers, regulatory consultancies, veterinary device producers and animal food companies operating across companion animal, livestock and aquaculture segments. Further information is available at international-animalhealth.com.